HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, double blind, vehicle-controlled evaluation of the effectiveness
and safety of HylaCareTM. The study will employ the patient as her own control, a commonly
used method for the evaluation of topical dermatologic agents. Each patient will be
randomized blindly as to whether the study serum will be applied to the medial or lateral
portion of the treated breast, using the nipple as the dividing line. The product and placebo
will also be applied to the contra-lateral breast in the same fashion, as a further control.
The study drug and placebo will be applied three (3) times daily.